ストックスクリーナーアプリを入手
96.06
2.45%
-2.41
アフターアワーズ：
95.00
-1.06
-1.10%
前日終値:
$98.47
開ける：
$99.4
24時間の取引高:
1.15M
Relative Volume:
1.53
時価総額：
$6.41B
収益：
$136.86M
当期純損益:
$-168.69M
株価収益率:
-34.19
EPS:
-2.81
ネットキャッシュフロー:
$-113.49M
1週間 パフォーマンス:
-7.52%
1か月 パフォーマンス:
-8.42%
6か月 パフォーマンス:
-0.41%
1年 パフォーマンス:
+66.66%
1日の値動き範囲:
$95.66
$101.61
1週間の範囲:
$95.66
$109.51
52週間の値動き範囲:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
名前
Rhythm Pharmaceuticals Inc
セクター
電話
857-264-4280
住所
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
96.06 | 6.57B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-25 | 開始されました | Citigroup | Buy |
| 2025-11-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-07-07 | 開始されました | Leerink Partners | Outperform |
| 2025-04-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2025-01-02 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Oppenheimer | Outperform |
| 2024-10-21 | 開始されました | Guggenheim | Buy |
| 2024-09-18 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-08-08 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-05 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 繰り返されました | Needham | Buy |
| 2022-03-02 | 再開されました | Stifel | Buy |
| 2022-02-17 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 再開されました | Goldman | Neutral |
| 2021-08-04 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-08-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-01-08 | 開始されました | Goldman | Sell |
| 2019-07-12 | アップグレード | Stifel | Hold → Buy |
| 2019-07-08 | 開始されました | Canaccord Genuity | Buy |
| 2019-03-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-09-07 | 再開されました | Morgan Stanley | Overweight |
| 2018-06-25 | 繰り返されました | Needham | Buy |
| 2018-06-15 | 繰り返されました | Needham | Buy |
| 2017-10-30 | 開始されました | BofA/Merrill | Buy |
| 2017-10-30 | 開始されました | Needham | Buy |
すべてを表示
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Rhythm’s LB54640 Trial Completion Sets Up Key Catalyst in Hypothalamic Obesity - TipRanks
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Earnings Miss: Can Rhythm Pharmaceuticals Inc expand into new marketsStock Surge & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Rhythm Pharmaceuticals at Guggenheim Summit: Expanding Horizons in Biotech By Investing.com - Investing.com Canada
Earnings Risk: Is Rhythm Pharmaceuticals Inc currently under institutional pressure2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Rhythm Pharma label expansion requests for obesity drug undergo U.S. EU reviews - MSN
Candriam S.C.A. Lowers Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Bond Watch: Will Rhythm Pharmaceuticals Inc benefit from green energy policies2025 Growth vs Value & Short-Term Trading Alerts - baoquankhu1.vn
Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock By Investing.com - Investing.com Canada
Insider Sell: Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $358,588.86 in Stock - MarketBeat
Penserra Capital Management LLC Acquires Shares of 30,436 Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals' CFO Hunter C. Smith to Speak at Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit - ChartMill
Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by New York State Common Retirement Fund - MarketBeat
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
WCM Investment Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
This High-Flying Growth Stock Is Hiding in Plain Sight - Finviz
Federated Hermes Inc. Has $174.50 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
EFG Asset Management North America Corp. Invests $2.05 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Bank Watch: Will Rhythm Pharmaceuticals Inc stock go up in YEARMarket Weekly Review & Daily Price Action Insights - baoquankhu1.vn
Aug Breakouts: What hedge funds are buying Rhythm Pharmaceuticals IncWall Street Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 37.5% Potential Upside in Biotech - DirectorsTalk Interviews
Aug Technicals: Is INVO Fertility Inc stock heavily shortedJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
(RYTM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
What is HC Wainwright's Estimate for RYTM FY2025 Earnings? - MarketBeat
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Turn A Profit? - Yahoo Finance
Zacks Research Downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Strong Sell - MarketBeat
Earnings Miss: Will Rhythm Pharmaceuticals Inc stock go up in YEARTake Profit & Weekly Return Optimization Alerts - baoquankhu1.vn
Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals - MSN
Rhythm Pharmaceuticals stock price target raised to $125 from $123 at H.C. Wainwright - Investing.com Canada
Breaking Down Rhythm Pharmaceuticals: 13 Analysts Share Their Views - Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for RYTM with Increased Price Target | RYTM Stock News - GuruFocus
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharm - Barchart.com
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Strong IMCIVREE Revenue Guidance For 2025 - Sahm
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3%Time to Sell? - MarketBeat
SG Americas Securities LLC Buys 13,369 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC - MarketBeat
Responsive Playbooks and the RYTM Inflection - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Gem with 38% Potential Upside - DirectorsTalk Interviews
What Rhythm Pharmaceuticals (RYTM)'s Strong IMCIVREE Revenue Beat Means For Shareholders - Sahm
Rhythm Pharmaceuticals stock price target raised to $130 from $120 at TD Cowen - Investing.com Canada
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Needham Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $148 | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Rhythm Pharmaceuticals (RYTM) Projects Strong Revenue Growth for 2025 - GuruFocus
Rhythm Pharmaceuticals announces preliminary, unaudited fourth quarter results - marketscreener.com
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - The Manila Times
How cyclical is Rhythm Pharmaceuticals Inc. (1RV) stock compared to rivalsJuly 2025 Reactions & High Win Rate Trade Tips - Улправда
Rhythm Pharmaceuticals Inc (RYTM) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):